Skip to main content

Table 1 Representative IPA categories associated with glutamate andcandesartan-glutamate comparison

From: An integrative genome-wide transcriptome reveals that candesartan is neuroprotective and a candidate therapeutic for Alzheimer’s disease

Categories Diseases or functions annotation p value No. of molecules
Cellular movement Cell movement 8.33E-52 170
Cell-to-cell signaling and interaction, cellular movement Recruitment of cells 1.61E-49 72
Hematological system development and function, tissue morphology Quantity of blood cells 4.80E-46 114
Inflammatory response Inflammation of organ 1.61E-45 119
Organismal injury and abnormalities Lesion formation 1.67E-44 73
Cardiovascular disease Vascular disease 1.33E-42 105
Immunological disease Systemic autoimmune syndrome 7.31E-41 108
Endocrine system disorders, gastrointestinal disease, metabolic disease Diabetes mellitus 1.60E-36 102
Cell death and survival Cell death 2.16E-35 191
Metabolic disease Glucose metabolism disorder 1.13E-33 109
Inflammatory disease Chronic inflammatory disorder 1.54E-33 94
Cardiovascular system development and function, organismal development Development of blood vessel 1.07E-27 83
Free radical scavenging Synthesis of reactive oxygen species 5.38E-27 59
  1. The number of molecules represents the number of genes differentially expressed between glutamate and candesartan + glutamate that are part of the pathway category. The whole ingenuity pathway analysis (IPA) output is provided as Additional file 3: Table S3
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193